Serum levels of insulin-like growth factor-I and insulin like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 1, 2005, Pages 13-15

  Wilczak, N ^a   Ramsaransing, G S M ^a   Mostert, J ^a   Chesik, D ^a   De Keyser, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Disease progression; Insulin like growth factor; Insulin like growth factor binding protein 3; Multiple sclerosis; Primary progressive MS

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RATING SCALE; RELAPSE; SCORING SYSTEM;

ADULT; BIOLOGICAL MARKERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RADIOIMMUNOASSAY;

EID: 13844307931     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1123oa     Document Type: Article

References (20)

1. Roth GA, Spada V, Hamill K, Bornstein MB. Insulin-like growth factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue. Brain Res Dev Brain Res 1995; 88: 102-108.
2. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 1986; 83: 822-26.
3. Mason JL, Ye P, Suzuki K, D'Ercole AJ, Matsushima GK. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 2000; 20: 5703-708.
4. Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD et al. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 1992; 70: 31-46.
5. Wilczak N, Schaaf M, Bredewold R, Streefland C, Teelken A, De Keyser J. Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. Neurosci Lett 1998; 257: 168-70
6. Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998; 50: 772-76.
7. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
8. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000; 47: 831-35.
9. Ramsaransing G, Maurits N, Zwanikken C, De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult Scler 2001; 7: 345-47.
10. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-54.
11. Butt AJ, Williams AC. IGFBP-3 and apoptosis - a license to kill? Apoptosis 2001; 6: 199-205.
12. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54: 145-48.
13. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 2001; 86: 1806-13.
14. Li H, Sun H, Qian ZM. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 2002; 23: 206-209.
15. Modric T, Silha JV, Shi Z, Gui Y, Suwanichkul A, Durham SK et al. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 2001; 142: 1958-67.
16. Rensink AA, Gellekink H, Otte-Holler I, ten Donkelaar HJ, de Waal RM, Verbeek MM et al. Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease. Acta Neuropathol (Berl) 2002; 104: 525-33.
17. Lovett-Racke AE, Bittner P, Cross AH, Carlino JA, Racke MK. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 1998; 101: 1797-804.
18. Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-57.
19. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312-16.
20. Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003; 250: 1094-98.